Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth C Page

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Genetic Medicine Reports|November 18, 2021
Updates in Prostate Cancer Research and Screening in Men at Genetically Higher RiskElizabeth K Bancroft, Holly Ni Raghallaigh, Elizabeth C Page, et al.
Genome Medicine|April 18, 2026
Developing a germline prostate cancer risk test incorporating rare and common variants, to inform clinical decisions: a route to precision oncologySarah Wakerell, Questa Karlsson, Susan Merson, et al.
The Oncologist|May 7, 2016
The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate CancerElena Castro, Christos Mikropoulos, Elizabeth K Bancroft, et al.
BJUI Compass|April 7, 2023
Serum testosterone and prostate cancer in men with germline <i>BRCA1/2</i> pathogenic variantsAlexander Dias, Mark N Brook, Elizabeth K Bancroft, et al.
BJU International|May 27, 2018
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutationsElizabeth K Bancroft, Sibel Saya, Elizabeth C Page, et al.
BJU International|June 5, 2024
The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriersElizabeth K Bancroft, Elizabeth C Page, Mark N Brook, et al.
The New England Journal of Medicine|April 11, 2025
Assessment of a Polygenic Risk Score in Screening for Prostate CancerJana K McHugh, Elizabeth K Bancroft, Edward Saunders, et al.
BJU International|September 16, 2010
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT studyAnita V Mitra, Elizabeth K Bancroft, Yolanda Barbachano, et al.
The Lancet. Oncology|October 22, 2021
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective studyElizabeth K Bancroft, Elizabeth C Page, Mark N Brook, et al.
Nature Genetics|September 22, 2009
Identification of seven new prostate cancer susceptibility loci through a genome-wide association studyRosalind A Eeles, Zsofia Kote-Jarai, Ali Amin Al Olama, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Genetic Medicine Reports|November 18, 2021
Updates in Prostate Cancer Research and Screening in Men at Genetically Higher RiskElizabeth K Bancroft, Holly Ni Raghallaigh, Elizabeth C Page, et al.
Genome Medicine|April 18, 2026
Developing a germline prostate cancer risk test incorporating rare and common variants, to inform clinical decisions: a route to precision oncologySarah Wakerell, Questa Karlsson, Susan Merson, et al.
The Oncologist|May 7, 2016
The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate CancerElena Castro, Christos Mikropoulos, Elizabeth K Bancroft, et al.
BJUI Compass|April 7, 2023
Serum testosterone and prostate cancer in men with germline <i>BRCA1/2</i> pathogenic variantsAlexander Dias, Mark N Brook, Elizabeth K Bancroft, et al.
BJU International|May 27, 2018
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutationsElizabeth K Bancroft, Sibel Saya, Elizabeth C Page, et al.
BJU International|June 5, 2024
The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriersElizabeth K Bancroft, Elizabeth C Page, Mark N Brook, et al.
The New England Journal of Medicine|April 11, 2025
Assessment of a Polygenic Risk Score in Screening for Prostate CancerJana K McHugh, Elizabeth K Bancroft, Edward Saunders, et al.
BJU International|September 16, 2010
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT studyAnita V Mitra, Elizabeth K Bancroft, Yolanda Barbachano, et al.
The Lancet. Oncology|October 22, 2021
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective studyElizabeth K Bancroft, Elizabeth C Page, Mark N Brook, et al.
Nature Genetics|September 22, 2009
Identification of seven new prostate cancer susceptibility loci through a genome-wide association studyRosalind A Eeles, Zsofia Kote-Jarai, Ali Amin Al Olama, et al.
Pageof 2